Literature DB >> 1969613

Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine.

L D Piro1, C J Carrera, D A Carson, E Beutler.   

Abstract

2-Chlorodeoxyadenosine is a simple purine nucleoside that has previously been shown to be effective in the treatment of low-grade malignant disorders of lymphoid tissue, including chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Because of these encouraging results, we treated 12 patients with another low-grade B-cell neoplasm, hairy-cell leukemia. The patients received 2-chlorodeoxyadenosine (0.1 mg per kilogram of body weight per day) by continuous infusion for seven days. All the patients responded to treatment. Eleven had complete remissions characterized by the normalization of peripheral blood and bone marrow and disappearance of tumor masses. The longest remission has been 3.8 years. None of the patients have relapsed, and the median duration of remission has been 15.5 months. No serious toxic reactions occurred as a result of 2-chlorodeoxyadenosine therapy. These results suggest that 2-chlorodeoxyadenosine may be the most effective therapy available for hairy-cell leukemia. The administration of 2-chlorodeoxyadenosine resulted in a higher rate of complete remission than is observed with interferon alfa, and it required no maintenance therapy. Its toxicity may be lower than that of deoxycoformycin, and the responses were achieved with single courses of treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1969613     DOI: 10.1056/NEJM199004193221605

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  69 in total

1.  Interferon-alpha is a very effective salvage therapy for patients with hairy cell leukemia relapsing after cladribine: a report of three cases.

Authors:  Mark A Hoffman
Journal:  Med Oncol       Date:  2010-05-28       Impact factor: 3.064

2.  Local application of antimycotics in mucormycosis cerebri: a case report.

Authors:  I Mohsenipour; M Schirmer; R Frank; F Geisen; E Semenitz; D zur Nedden; G Konwalinka
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-11       Impact factor: 10.154

Review 3.  Hairy cell leukemia: present and future directions.

Authors:  Robert J Kreitman
Journal:  Leuk Lymphoma       Date:  2019-05-09

4.  Effects of 2-chloroadenine substitution in DNA on restriction endonuclease cleavage reactions.

Authors:  P Hentosh; J C McCastlain
Journal:  Nucleic Acids Res       Date:  1991-06-11       Impact factor: 16.971

5.  Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia.

Authors:  Bartlomiej M Getta; Kaitlin M Woo; Sean Devlin; Jae H Park; Omar Abdel-Wahab; Alan Saven; Kanti Rai; Martin S Tallman
Journal:  Br J Haematol       Date:  2016-06-28       Impact factor: 6.998

Review 6.  Interferon-alpha in malignant and viral diseases. A review.

Authors:  R T Dorr
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

7.  Granulocyte colony-stimulating factor (rh G-CSF) as an adjunct to interferon alpha therapy of neutropenic patients with hairy cell leukemia.

Authors:  C Lorber; A Willfort; L Ohler; U Jäger; I Schwarzinger; K Lechner; K Geissler
Journal:  Ann Hematol       Date:  1993-07       Impact factor: 3.673

Review 8.  The optimal management of hairy cell leukaemia.

Authors:  R Gollard; T C Lee; L D Piro; A Saven
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

9.  Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma.

Authors:  Kensei Tobinai; Naokuni Uike; Yoshio Saburi; Takaaki Chou; Tetsuya Etoh; Masato Masuda; Fumio Kawano; Masao Matsuoka; Hirokuni Taguchi; Torahiko Makino; Yoshinobu Asano; Kazuo Tamura; Yasuo Ohashi
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

Review 10.  Update on the biology and treatment options for hairy cell leukemia.

Authors:  Preetesh Jain; Naveen Pemmaraju; Farhad Ravandi
Journal:  Curr Treat Options Oncol       Date:  2014-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.